375 related articles for article (PubMed ID: 29938225)
1. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.
Durant ST; Zheng L; Wang Y; Chen K; Zhang L; Zhang T; Yang Z; Riches L; Trinidad AG; Fok JHL; Hunt T; Pike KG; Wilson J; Smith A; Colclough N; Reddy VP; Sykes A; Janefeldt A; Johnström P; Varnäs K; Takano A; Ling S; Orme J; Stott J; Roberts C; Barrett I; Jones G; Roudier M; Pierce A; Allen J; Kahn J; Sule A; Karlin J; Cronin A; Chapman M; Valerie K; Illingworth R; Pass M
Sci Adv; 2018 Jun; 4(6):eaat1719. PubMed ID: 29938225
[TBL] [Abstract][Full Text] [Related]
2. Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice.
Karlin J; Allen J; Ahmad SF; Hughes G; Sheridan V; Odedra R; Farrington P; Cadogan EB; Riches LC; Garcia-Trinidad A; Thomason AG; Patel B; Vincent J; Lau A; Pike KG; Hunt TA; Sule A; Valerie NCK; Biddlestone-Thorpe L; Kahn J; Beckta JM; Mukhopadhyay N; Barlaam B; Degorce SL; Kettle J; Colclough N; Wilson J; Smith A; Barrett IP; Zheng L; Zhang T; Wang Y; Chen K; Pass M; Durant ST; Valerie K
Mol Cancer Ther; 2018 Aug; 17(8):1637-1647. PubMed ID: 29769307
[TBL] [Abstract][Full Text] [Related]
3. ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis.
Tew BY; Kalfa AJ; Yang Z; Hurth KM; Simon T; Abnoosian E; Durant ST; Hamerlik P; Salhia B
Clin Cancer Res; 2023 Nov; 29(21):4492-4503. PubMed ID: 37585496
[TBL] [Abstract][Full Text] [Related]
4. Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors.
Talele S; Zhang W; Chen J; Gupta SK; Burgenske DM; Sarkaria JN; Elmquist WF
J Pharmacol Exp Ther; 2022 Oct; 383(1):91-102. PubMed ID: 36137710
[TBL] [Abstract][Full Text] [Related]
5. CRISPR Screen of Druggable Targets in Small Cell Lung Cancer Identified ATM Inhibitor (AZD1390) as a Radiosensitizer.
Ran X; Wu BX; Shi M; Song L; Nixon K; Philip V; He HH; Tsao MS; Lok BH
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1308-1314. PubMed ID: 38104868
[TBL] [Abstract][Full Text] [Related]
6. Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study.
Jucaite A; Stenkrona P; Cselényi Z; De Vita S; Buil-Bruna N; Varnäs K; Savage A; Varrone A; Johnström P; Schou M; Davison C; Sykes A; Pilla Reddy V; Hoch M; Vazquez-Romero A; Moein MM; Halldin C; Merchant MS; Pass M; Farde L
Neuro Oncol; 2021 Apr; 23(4):687-696. PubMed ID: 33123736
[TBL] [Abstract][Full Text] [Related]
7. ATM inhibition enhances the efficacy of radiation across distinct molecular subgroups of pediatric high-grade glioma.
Xie J; Kuriakose T; Bianski B; Twarog N; Savage E; Xu K; Zhu X; He C; Hansen B; Wang H; High A; Li Y; Rehg JE; Tillman HS; Freeman BB; Rankovic Z; Onar-Thomas A; Fan Y; Wu G; Peng J; Miller S; Baker SJ; Shelat AA; Tinkle CL
Neuro Oncol; 2023 Oct; 25(10):1828-1841. PubMed ID: 36971093
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM.
Hickson I; Zhao Y; Richardson CJ; Green SJ; Martin NM; Orr AI; Reaper PM; Jackson SP; Curtin NJ; Smith GC
Cancer Res; 2004 Dec; 64(24):9152-9. PubMed ID: 15604286
[TBL] [Abstract][Full Text] [Related]
9. Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization.
Chen J; Laverty DJ; Talele S; Bale A; Carlson BL; Porath KA; Bakken KK; Burgenske DM; Decker PA; Vaubel RA; Eckel-Passow JE; Bhargava R; Lou Z; Hamerlik P; Harley B; Elmquist WF; Nagel ZD; Gupta SK; Sarkaria JN
Sci Transl Med; 2024 Feb; 16(734):eadj5962. PubMed ID: 38354228
[TBL] [Abstract][Full Text] [Related]
10. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation.
Biddlestone-Thorpe L; Sajjad M; Rosenberg E; Beckta JM; Valerie NC; Tokarz M; Adams BR; Wagner AF; Khalil A; Gilfor D; Golding SE; Deb S; Temesi DG; Lau A; O'Connor MJ; Choe KS; Parada LF; Lim SK; Mukhopadhyay ND; Valerie K
Clin Cancer Res; 2013 Jun; 19(12):3189-200. PubMed ID: 23620409
[TBL] [Abstract][Full Text] [Related]
11. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.
Cui Y; Palii SS; Innes CL; Paules RS
Cell Cycle; 2014; 13(22):3541-50. PubMed ID: 25483091
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma.
Gil del Alcazar CR; Hardebeck MC; Mukherjee B; Tomimatsu N; Gao X; Yan J; Xie XJ; Bachoo R; Li L; Habib AA; Burma S
Clin Cancer Res; 2014 Mar; 20(5):1235-48. PubMed ID: 24366691
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin-mediated radiosensitization of non-small cell lung cancer cells is stimulated by ATM inhibition.
Toulany M; Mihatsch J; Holler M; Chaachouay H; Rodemann HP
Radiother Oncol; 2014 May; 111(2):228-36. PubMed ID: 24857596
[TBL] [Abstract][Full Text] [Related]
14. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion.
Golding SE; Rosenberg E; Valerie N; Hussaini I; Frigerio M; Cockcroft XF; Chong WY; Hummersone M; Rigoreau L; Menear KA; O'Connor MJ; Povirk LF; van Meter T; Valerie K
Mol Cancer Ther; 2009 Oct; 8(10):2894-902. PubMed ID: 19808981
[TBL] [Abstract][Full Text] [Related]
15. Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response.
Huang CY; Hsieh FS; Wang CY; Chen LJ; Chang SS; Tsai MH; Hung MH; Kuo CW; Shih CT; Chao TI; Chen KF
Eur J Cancer; 2018 Oct; 102():10-22. PubMed ID: 30103095
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and toxicity of ATM inhibition in glioblastoma initiating cells-driven tumor models.
Frosina G; Marubbi D; Marcello D; Vecchio D; Daga A
Crit Rev Oncol Hematol; 2019 Jun; 138():214-222. PubMed ID: 31092378
[TBL] [Abstract][Full Text] [Related]
17. BIBR1532, a Selective Telomerase Inhibitor, Enhances Radiosensitivity of Non-Small Cell Lung Cancer Through Increasing Telomere Dysfunction and ATM/CHK1 Inhibition.
Ding X; Cheng J; Pang Q; Wei X; Zhang X; Wang P; Yuan Z; Qian D
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):861-874. PubMed ID: 31419512
[TBL] [Abstract][Full Text] [Related]
18. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
[TBL] [Abstract][Full Text] [Related]
19. ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration.
Fròsina G; Profumo A; Marubbi D; Marcello D; Ravetti JL; Daga A
Radiat Oncol; 2018 Apr; 13(1):76. PubMed ID: 29685176
[TBL] [Abstract][Full Text] [Related]
20. Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood-Brain Barrier: The Discovery of AZD1390.
Pike KG; Hunt TA; Barlaam B; Benstead D; Cadogan E; Chen K; Cook CR; Colclough N; Deng C; Durant ST; Eatherton A; Goldberg K; Johnström P; Liu L; Liu Z; Nissink JWM; Pang C; Pass M; Robb GR; Roberts C; Schou M; Steward O; Sykes A; Yan Y; Zhai B; Zheng L
J Med Chem; 2024 Feb; 67(4):3090-3111. PubMed ID: 38306388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]